The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated. [ Time Frame: per the study, the pt will be on GH treatement until the physician instructs them to stop ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney Disease
Greater than 18 years old
Not a patient at the UC Davis Medical Center pediatric clinic
Keywords provided by University of California, Davis:
Growth Failure AND
Chronic Renal Insufficiency OR
End Stage Renal Disease
Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Bone Diseases, Developmental
Bone Diseases, Endocrine
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases